Table 1.
Study and population characteristics
| Author, year | Technique | No. patients | Age, mean years (SD) | Mean follow-up time | Clinical success | Partial clinical success | Complete clinical success | 24 h esophageal pH monitoring | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DeMeester score mean (SD) | Mean esophageal acid exposure time (%) (Ph＜4) (SD) | |||||||||||||
| Preoperation | Postoperation | Preoperation | Postoperation | |||||||||||
| Inoue et al. [12], 2014 | ARMS | 10 | NR | 2 months | 10 | 0 | 10 | NR | 29.1 | 3.1 | ||||
| Ota et al. [22], 2014 | ARMS | 13 | NR | 6 months | 12 | 0 | 12 | NR | 10.4 (±15.5) | 7.4 (±10.6) | ||||
| Bapaye et al. [25], 2017 | ARMS | 15 | 40.8 (19.2) | 1 months | 15 | 4 | 11 | 85.8 | 5.9 | NR | ||||
| Benias et al. [15], 2018 | RAP | 10 | 56.5 | 5–27 months | 10 | 0 | 10 | NR | NR | |||||
| Hu et al. [16], 2018 | PECC | 16 | 53 | 3, 6 months | 16 | 0 | 16 | 125.5 (±89.64) | 20.32 (±15.22) | 35.55 (±26.2) | 4.72% (±3.78%) | |||
| Patil et al. [17], 2019 | ARMS-C (cap-EMR) | 62 | 36 (9.9) | 2, 6, 12 months | 55 | 12 | 43 | 76.8 (18.3) | 14.3 (6.1) | NR | ||||
| Hedberg et al. [19], 2019 | ARM-b | 19 | 57.1 | 3 week, 6 months | 13 | 0 | 13 | NR | NR | |||||
| Prasad et al. [32], 2019 | ARMS | 11 | 41–60 | 6 months | 8 | 0 | 8 | NR | NR | |||||
| Yoo et al. [18], 2020 | ARMS-C | 33 | 51.3 (16.3) | 6 months | 31 | 10 | 21 | 14.3 (10.9) | 7.7 (9,4) | 3.1(3.1) | 1.8 (2.4) | |||
| Monino et al. [27], 2020 | ARM-b | 21 | 56.78 (14.47) | 5, 10 months | 16 | 4 | 12 | NR | NR | |||||
| Inoue et al. [21], 2020 | ARMA | 12 | 54.4 | 2 months | 12 | 0 | 12 | 33.5 | 2.8 | 9 | 0.5 | |||
| Hernandez et al. [24], 2020 | ARAT(ARMA) | 108 | 36.5 | 3,6,12,24,36 months | 96 | 0 | 96 | 42.5 | 9.1 | 18.8 | 2.8 | |||
| Debourdeau et al. [20], 2020 | ARMS-b | 6 | 44(7.5) | 3 months | 3 | 2 | 1 | NR | NR | |||||
| Wong et al. [28], 2020 | ARMS-b | 33 | 55 (17) | 6 months, 1 year, 2 years | 30 | 0 | 30 | NR | NR | |||||
| Sumi et al. [23], 2021 | ARMS | 109 | 54 (15.7) | 2–6 months, 1 year | 42 | 0 | 42 | 64.4 (75.7) | 24.9 (36) | 20.8 (24.3) | 6.9 (10.4) | |||
| Author, year | GERD-HRQL score | GERD-Q score mean (SD) | Adverse events | The use of acid inhibitors | Hill grade | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dysphagia | Bleeding | Others | ||||||||||||
| Preoperation | Preoperation | Preoperation | Preoperation | Post-operation | ||||||||||
| Inoue et al. [12], 2014 | NR | NR | 2 | NR | NR | All discontinued | Grade I | |||||||
| Ota et al. [22], 2014 | NR | NR | 1 | NR | NR |
3 discontinued 3 reduced in dose 6 at the usual dose |
NR | |||||||
| Bapaye et al. [25], 2017 | 40.4 | 7.6 | NR | 1 | 0 | 2 | NR | NR | ||||||
| Benias et al. [15], 2018 | 26.6 (±3.9) | 4.3 (±2.4) | NR | 1 | NR | NR |
6 discontinued 4 reduced in dose |
Grade I | ||||||
| Hu et al. [16], 2018 | 36.5 | 10 | NR | 3 | 0 | 1 | NR | NR | ||||||
| Patil et al. [17], 2019 | NR | 10.6 (1.9) | 3.4 (1.5) | 5 | 0 | 4 |
43 discontinued 12 reduced in dose 7 at the usual dose |
NR | ||||||
| Hedberg et al. [19], 2019 | Improved | NR | 3 | 1 | 1 | 13 discontinued | NR | |||||||
| Prasad et al. [32], 2019 | NR | NR | 0 | 0 | 0 | NR | NR | |||||||
| Yoo et al. [18], 2020 | NR | 11.1 (3.1) | 6.8 (3.1) | 2 | 0 | 0 |
21 discontinued 10 reduced in dose |
Grade I | ||||||
| Monino et al. [27], 2020 | 25.6 (8.8) | 16.8 (6.4) | 12.5 (1.5) | 9 (2) | 3 | 1 | 0 |
3 months 76% Decrease/discontinue 6 months 72% Decreased/discontinued |
19 improved | |||||
| Inoue et al. [21], 2020 | 30.5 | 12 | NR | 1 | 0 | 0 | 5 discontinued | Grade I (1.9–0.5) | ||||||
| Hernandez et al. [24], 2020 | 36.5 | 10 | NR | 14 | 0 | 0 | 78.6% 3 years discontinued | Grade I | ||||||
| Debourdeau et al. [20], 2020 | 30.6 (7.7) | 6.8 (3.7) | 13.3 (1.1) | 6.2 (4.0) | 1 | 1 | 0 |
1 discontinued 2 reduced in dose 3 at the usual dose |
NR | |||||
| Wong et al. [28], 2020 | 16 (12) | 6 (7.1) | NR | 3 | 1 | 1 | 90.9% discontinued | Grade I | ||||||
| Sumi et al. [23], 2021 | NR | NR | 14 | 2 | 1 | 50% 1 year discontinued | NR | |||||||
GERD-HRQL, GERD-Health Related Quality of Life, GERD-Q GERD-questionnaire, mon month, SD standard deviation, RAP resection and plication, PECC Peroral endoscopic cardinal constriction, ARMS-C anti-reflux mucosectomy using cap-assisted endoscopic mucosal resection (EMR-C), ARAT antireflux ablation therapy, ARMA anti-reflux mucosal ablation, ARMS-b antireflux mucosectomy band, NR not reported